MARKET

NKTR

NKTR

Nektar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.63
-0.43
-2.38%
Opening 12:37 03/31 EDT
OPEN
17.84
PREV CLOSE
18.06
HIGH
18.07
LOW
17.52
VOLUME
394.62K
TURNOVER
--
52 WEEK HIGH
37.00
52 WEEK LOW
13.63
MARKET CAP
3.13B
P/E (TTM)
-7.0002
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NKTR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NKTR stock price target is 31.85 with a high estimate of 80.00 and a low estimate of 18.00.

EPS

NKTR News

More
  • Benzinga's Top Upgrades, Downgrades For March 30, 2020
  • Benzinga · 1d ago
  • Raymond James likes Amgen in premarket analyst action
  • Seeking Alpha - Article · 1d ago
  • Goldman Sachs Upgrades Nektar Therapeutics to Neutral, Raises Price Target to $20
  • Benzinga · 1d ago
  • Hedge Funds Are Betting On Nektar Therapeutics (NKTR)
  • Insider Monkey · 1d ago

Industry

Biotechnology & Medical Research
-1.43%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About NKTR

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
More

Webull offers kinds of Nektar Therapeutics stock information, including NASDAQ:NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions.